Virpax Pharmaceuticals
VRPX
Market cap $3M

0.6142 USD

-0.0304

4.72%

At close Nov 15, 4:00 PM EST

1 day

-4.72%

5 days

-16.72%

1 month

38.96%

3 months

-27.66%

6 months

-21.26%

Year to date

-80.75%

1 year

-91.72%

5 years

-99.06%

10 years

-99.06%

About: Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Employees: 7

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

747% more capital invested

Capital invested by funds: $12.6K [Q2] → $107K (+$94K) [Q3]

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

25% more funds holding

Funds holding: 8 [Q2] → 10 (+2) [Q3]

2.25% more ownership

Funds ownership: 0.89% [Q2] → 3.14% (+2.25%) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VRPX.

See Analyst Rankings

Financial journalist opinion

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per pr.

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $5.0 million of shares of the Company's common stock, par value 0.00001 per share, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per.

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 Second Quarter Results and Recent Developments.

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at Sidoti Virtual Investor Conference August 14-15.

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

Virpax Regains Compliance with Nasdaq Minimum Bid Price

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Regains Compliance with Nasdaq Minimum Bid Price.

Virpax Regains Compliance with Nasdaq Minimum Bid Price

Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday.

Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher

Why Is Virpax Pharmaceuticals (VRPX) Stock Up 98% Today?

Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is rocketing higher on Wednesday after the preclinical-stage pharmaceutical company announced positive results from a swine model pilot study. Virpax Pharmaceuticals has released results from its swine model study of Probudur.

Why Is Virpax Pharmaceuticals (VRPX) Stock Up 98% Today?

Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?

Wednesday, Virpax Pharmaceuticals Inc VRPX released results for a Swine Model pilot study for Probudur, Virpax's long-acting liposomal bupivacaine formulation injected at a wound site to provide immediate and extended pain relief.

Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?

Spotting Penny Stocks With Breakout Potential, 3 Tips

Spotting penny stocks with breakout potential requires a keen understanding of several key factors that can indicate imminent growth. One crucial aspect is identifying companies with strong fundamentals.

Spotting Penny Stocks With Breakout Potential, 3 Tips

See News Rankings

Charts implemented using Lightweight Charts™